Event

Kelly Chin

MD
Univ of Texas Southwestern Medical Center;University of Texas Southwestern;University of Texas, Southwestern Medical Center;UT Southwestern;UT Southwestern Medical Center

Hossein Ardeschir. Ghofrani

MD
Justus Liebig University of Giessen;Univ Hosp Giessen and Marburgh GmbH;Universities of Giessen and Marburg Lung Center;University of Giessen and Marburg Lung Center, member of the German Center of Lu

Olivier Sitbon

MD, PhD
Hôpital Bicêtre;Hopital De Bicetre;Université Paris-Sud, Le Kremlin Bicêtre

Gérald Simonneau

MD, PhD
Université Paris-Sud, Le Kremlin Bicêtre

Lewis J. Rubin

MD
University of California

Irene Marthe. Lang

MD, PhD
AKH-Vienna, Medical University of Vienna;Allgemeines Krankenhaus;Medical Univ of Vienna;Medical University of Vienna;Medical University Vienna

Victor F. Tapson

MD
Cedars Sinai;Cedars-Sinai;Cedars-Sinai Medical Center

Nazzareno Galié

MD, PhD
University of Bologna;University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine - DIMES;University of Bologna, Department of Specialized, Diagnostic and Experimental Medicin

Richard Channick

MD
Massachusetts General Hospital

Vallerie V. McLaughlin

MD
Director of Pulmonary Hypertension Program, University of Michigan;University of Michigan;University of Michigan Medical Center

Sean Gaine

MD, PhD
Mater Misericordiae University Hospital

Ralph Preiss

MD
Actelion Pharmaceuticals Ltd

Lilla Di Scala

PhD
Actelion Pharmaceuticals Ltd

Marius M. Hoeper

MD
Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, member of the German Ce;Hannover Medical School;Hannover Medical School and German Center of Lung Research;MH Hannover

Association of NT-proBNP and Long-Term Outcome in Pulmonary Arterial Hypertension (PAH): Insights from the Phase III GRIPHON Study with Selexipag